Role of implicit bias in pediatric cancer clinical trials and enrollment recommendations among pediatric oncology providers

Background: Provider implicit bias could negatively affect the doctor-patient communication. In this study, the authors measured implicit bias training in pediatric oncology providers and exposure implicit association test (IATs). They then assessed the association between IATs to race and socioeconomic status (SES) and the recommendation for the registration of clinical trials.

Methods: A prospective multisite study conducted to measure implicit bias among providers of oncology at the Hospital St. Jude Children’s Research and affiliated clinics. An IAT is used to assess the bias in the domain of race and SES. sketches of use cases to determine the relationship between bias and provider recommendation for trial registration. Data were analyzed using Student’s t test or Wilcoxon test for the comparison and the Jonckheere-Terpstra test is used for the association.

Results: Of the 105 number of the participants, 95 (90%) did not take an IAT and 97 (92%) do not have an implicit bias training before. A great effect was found for (bias towards) high SES (Cohen d, 1.93) and the European American race (Cohen d, 0.96). The majority of participants (90%) had a score sketch of 3 or 4, which indicates the recommendation for trial enrollment for part or the entire sketch. IAT and vignette scores did not significantly differ between providers on the Hospital St. Jude Children’s Research or affiliated clinics. No relationship was found between IAT and score sketches for the race (P = 0.58) or SES (P = 0.82).

Conclusions: The authors noted deficiencies prior exposure bias implicit self-assessment and training. Although providers show a preference for high SES and racial America Europe, this does not seem to affect the recommendation for registration of clinical trials that assessed by the sketch.

Through the years the ability to suppress angiogenesis has been utilized in the field of oncology. This efficiency is well documented and indications continue to grow, although the impact is often somewhat limited, as we argue in this review. Recent evidence suggests that angiogenesis inhibition may be a clinically meaningful treatment through several channels but less than the limit biomarker individual approach. The tumor microenvironment are anti-immune and anti-angiogenic drug combinations and immunotherapy has demonstrated impressive results and can change therapy in the years to come.

COVID-19 Pandemic Impact on Student and Resident Teaching and Training in Surgical Oncology

The COVID 19th pandemic has greatly changed the personal and professional interactions and behaviors worldwide. The effects of this pandemic and the measures taken have changed our health system, which in turn has affected the surgical medical education and training. In the face of constant interruption of surgical education and training during the pandemic outbreak, structured and innovative concepts and customized curriculum that is important to ensure the high quality of medical care. While efforts were made to prevent the virus from spreading, it is important to analyze and assess the impact of this crisis on medical education, surgical training and teaching in general and certainly in the field of surgical oncology.

Against this background, in this paper we introduce a practical and creative recommendations for the continuity of students and residents training and medical and surgical teaching. It includes a virtual curriculum of education, skill development classes, video-based feedback and simulation in the field of oncology surgical specialties. In conclusion, the effect COVID 19 Surgical Training and Teaching, certainly in the field of Surgical Oncology, challenging.

 Role of implicit bias in pediatric cancer clinical trials and enrollment recommendations among pediatric oncology providers
Role of implicit bias in pediatric cancer clinical trials and enrollment recommendations among pediatric oncology providers

Multiomic General Oncology Database Integration in Bioconductor

Objective: Investigation of the molecular basis for the development, progress and treatment of cancer are increasingly using complementary genomic tests to collect data multiomic, but the management and analysis of the data is still complex. The cBioPortal for genomics of cancer today provides data multiomic of> 260 general studies, including The Cancer Genome Atlas (TCGA) set of data, but the integration of various types of data the remains challenging and error prone to computational methods and tools to use these resources , The latest advances in data infrastructure in Bioconductor project enables new and powerful approach to creating this integrated representation multiomic, pan-cancer database

.
Methods: We provide a set of packages R / Bioconductor to work with legacy data and data TCGA cBioPortal, with special consideration for the loading time; efficient representation in and out of memory; Analytics platform; and integrative framework, as MultiAssayExperiment.

VEGFR binding peptide IVLS / RKRKRKKSRYIVLS

007-59 100 μg
EUR 171.72

Rabbit Anti-Human VEGFR-1 Flt-1 (Peptide), soluble

102-PA21 100ug
EUR 240

Anti-Human VEGFR-1/Flt-1 (Peptide), soluble Antibody

102-PA21S 100 µg
EUR 126
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Human FLT-1/VEGFR-1 Control/blocking peptide #1

FLT11-P 100 ug
EUR 196.8

VEGFR-1/Flt1/ Rat VEGFR- 1/ Flt1 ELISA Kit

ELA-E0147r 96 Tests
EUR 1063.2

Human FLT-4/VEGFR-3 control/blocking peptide #2

FLT42-P 100 ug
EUR 196.8

Human VEGFR-1/Flt1 ELISA Kit

EHV0045 96Tests
EUR 625.2

Human Vascular Endothelial Growth Factor Receptor 1 / VEGFR1 (FLT1) Peptide (OVA)

abx165607-100g 100 µg
EUR 1800

Human Vascular Endothelial Growth Factor Receptor 1 / VEGFR1 (FLT1) Peptide (OVA)

abx165607-10g 10 µg
EUR 475

Human Vascular Endothelial Growth Factor Receptor 1 / VEGFR1 (FLT1) Peptide (OVA)

abx165607-50g 50 µg
EUR 575

Mouse FLT-4/VEGFR-3 Control/blocking peptide #1

FLT41-P 100 ug
EUR 196.8

GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human)

029-03 500 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human)

029-04 100 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human)

029-05 20 μg
EUR 267.84

Rat VEGFR-1/Flt1 ELISA Kit

ERV0045 96Tests
EUR 625.2

Goat VEGFR-1/Flt1 ELISA Kit

EGTV0045 96Tests
EUR 625.2

Mouse VEGFR-1/Flt1 ELISA Kit

EMV0045 96Tests
EUR 625.2

Rabbit VEGFR-1/Flt1 ELISA Kit

ERTV0045 96Tests
EUR 625.2

Canine VEGFR-1/Flt1 ELISA Kit

ECV0045 96Tests
EUR 625.2

Bovine VEGFR-1/Flt1 ELISA Kit

EBV0045 96Tests
EUR 625.2

Porcine VEGFR-1/Flt1 ELISA Kit

EPV0045 96Tests
EUR 625.2

Anserini VEGFR-1/Flt1 ELISA Kit

EAV0045 96Tests
EUR 625.2

Human VEGFR1-14/Flt1-14, soluble Recombinant Protein

S01-072 20 µg
EUR 252
Description: A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.

Human VEGFR1-14/Flt1-14, soluble Recombinant Protein

S01-072S 5 µg
EUR 126
Description: A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.

Rabbit anti VEGFR-1/Flt-1 (human)

102-PA20S 100ug
EUR 240

Guinea Pig VEGFR-1/Flt1 ELISA Kit

EGV0045 96Tests
EUR 625.2

Rabbit Anti-Human VEGFR-2/KDR (Peptide), soluble

102-PA19 100ug
EUR 240

Anti-Human VEGFR-2/KDR (Peptide), soluble Antibody

102-PA19S 100 µg
EUR 126
Description: VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Anti-Mouse VEGFR-2/Flk-1 (Peptide), soluble Antibody

103-PA19S 100 µg
EUR 126
Description: The antibody recognizes solely the endogenous soluble form of mouse vascular endothelial growth factor receptor 2, alos known as CD309, VEGFR2, KDR, protein tyrosine kinase receptor flk-1, and fetal liver kinase-1. The endogenous soluble mouse esFlk-1 generated by alternative splicing consists of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP. Flk-1 is a member of the tyrosine protein kinase family, sub-family CSF-1/PDGF, that contains a single pass transmembrane receptor with a protein kinase domain and seven immunoglobulin-like domains in the extracellular region. Flk-1 is expressed at high levels in adult heart, lung, kidney, brain, and skeletal muscle; other tissues express at lower levels. Flk-1 is a receptor for VEGF-A or fully processed VEGF-C; ligand binding plays a key role in vascular development and vascular permeability.

Gastrin Releasing Peptide (GRP) (14-27) (Human, Porcine)

027-16 500 μg
EUR 108

Rabbit Anti-Mouse VEGFR-2 Flk-1 (Peptide), soluble

103-PA19 100ug
EUR 240

Mouse anti VEGFR-1/Flt-1 (#EWC) (human)

101-M24 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EIC) (human)

101-M26 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EWF) (human)

101-M28 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EWI) (human)

101-M30 100ug
EUR 297.6

Anti-Inflammatory Peptide 1

004-01 200 μg
EUR 27

Mouse anti VEGFR-3/Flt-4 (#1) (human)

101-M36 100ug
EUR 297.6

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0001 1.0mg
EUR 691.2
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0005 5.0mg
EUR 2648.4
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat)

029-08 200 μg
EUR 64.8

Mouse anti VEGFR-1/Flt-1-Biotin (#EWF) (human)

101-MBi28 50ug
EUR 297.6

Rabbit anti FLT1 Peptide Polyclonal Antibody

TA354699 100 µg Ask for price

Anti-Human VEGFR-1/Flt-1 Antibody

102-PA20 200 µg
EUR 173.25
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

102-PABi20 50 µg
EUR 157.5
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

101-MBi24 50 µg
EUR 246.75
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

101-MBi30 50 µg
EUR 189
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

anti- VEGFR-1/FLT-1 antibody

FNab09393 100µg
EUR 606.3
Description: Antibody raised against VEGFR-1/FLT-1

Rabbit anti VEGFR-3/Flt-4 (human)

102-PA22AG 50ug
EUR 240

Rabbit anti VEGFR-3/Flt-4 (human)

102-PA22S 100ug
EUR 240

Mouse anti VEGFR-3/Flt-4-Biotin (#1) (human)

101-MBi36 50ug
EUR 297.6

Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human)

072-17 100 μg
EUR 370.44

Peptide YY (PYY) (1-36)-Gly (Human)

059-07 100 μg
EUR 295.92

RFamide-Related Peptide 1 (RFRP-1) (Human)

048-42 500 μg
EUR 177.12

Peptide Lv (Human)

008-71 100 μg
EUR 405

Nesfatin-1-Like Peptide (NLP) (Human)

009-83 100 μg
EUR 469.8

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

201-12-0249 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1,Flt1) Elisa Kit

EK714043 96 Wells
EUR 0.42

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1,Flt1) Elisa Kit

EK711523 96 Wells
EUR 0.18

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

EK10449 96Т
EUR 799

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-48T 48T
EUR 511.7

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-5x96T 5x96T
EUR 3472.25

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-96T 96T
EUR 731

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-48T 48T
EUR 346.8

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-96T 96T
EUR 559.2

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

CSB-E11885h-24T 1 plate of 24 wells
EUR 198
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

1-CSB-E11885h
  • Ask for price
  • Ask for price
  • Ask for price
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

AE43478HU-48Tests 48 Tests
EUR 325
Description: Human (Homo sapiens)

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

AE43478HU-96Tests 96 Tests
EUR 610
Description: Human (Homo sapiens)

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

QY-E00705 96T
EUR 433.2

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

RK10114 96T
EUR 280

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

YLA1567HU-48T 48T Ask for price

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

YLA1567HU-96T 96T Ask for price

Peptide YY (PYY) (Human) - Antibody

H-059-01 100 μl
EUR 469.8

FLT1 Blocking Peptide

BF0131-BP 1mg
EUR 234

SHLP1 / Small Humanin-Like Peptide 1 (Human)

018-75 100 μg
EUR 263.52

Human Vascuoar Endothelial Cell Growth Factor Receptor 1, VEGFR-1 / Flt1 GENLISA ELISA

KBH0248 1 x 96 wells
EUR 286

Mouse FLK-1/VEGFR-2 control/blocking peptide # 1

FLK11-P 100 ug
EUR 196.8

[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human)

048-43 200 μg
EUR 177.12

Gastrin Releasing Peptide (GRP) (1-16) (Human)

027-08 1 mg
EUR 177.12

Gastrin Releasing Peptide (GRP) (1-17) (Human)

027-42 200 μg
EUR 189

Peptide YY (PYY) (Human)

059-01 200 μg
EUR 119.88

Human VEGF Receptor 1 (VEGFR1, Flt1)

hAP-0001A 50ug
EUR 400

Anti-Inflammatory Peptide 2

004-02 200 μg
EUR 27

Anti-Inflammatory Peptide 3

004-03 200 μg
EUR 27

Peptide YY (PYY) (3-36) (Human) - Antibody

H-059-02 100 μl
EUR 604.8

TCAP-1 / Teneurin C-terminal Associated Peptide-1 (Human)

020-16 100 μg
EUR 317.52

Anti-Mouse VEGFR-1/Flt-1 Antibody

103-M31 100 µg
EUR 399
Description: Vascular Endothelial Growth Factor (VEGF or VEGF-A) family members are major mediators of vasculogenesis and angiogenesis. Specifically, biological activities attributed to VEGFs include: mitogenic activity on endothelial cells, increased permeability of endothelial cells to proteins, stimulation of monocyte migration across endothelial cells and angiogenic activity. Three VEGF family receptors have been described: Flt-1 (fms-like tyrosine kinase) also known as VEGF R1, KDR (kinase-insert domain-containing receptor) also known as Flk-1 and VEGF R2, and Flt-4 also known as VEGF R3. The three receptors contain seven extracellular immunoglobulin-like domains and share substantial sequence homology. In addition, neuropilin-1, a neuronal receptor, also acts as a co-receptor for VEGF when expressed on vascular endothelial cells, endothelial cell progenitors and monocytes. VEGF R1 is expressed primarily on endothelial cells but is also found on human peripheral blood monocytes. Through its endothelial mitogenic and hyperpermeability activities, VEGF influences a variety of immune functions related to wound healing and blood protein traffic across endothelial barriers.

prepro-Endothelin-1 (ET-1) Like Peptide (109-130) amide (Human)

023-11 100 μg
EUR 355.32

Anti-Angiogenic Peptide Library

L-008A 88 peptides
EUR 6067.44

GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human)

029-06 100 μg
EUR 114.48

Nesfatin-1-Like Peptide(NLP) (Human) - RIA Kit

RK-009-83 125 tubes
EUR 980.64

RFamide-Related Peptide 1 (RFRP-1) (Human) - FAM Labeled

FG-048-42A 1 nmol
EUR 336.96

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody

H-064-07 50 μl
EUR 238.68

Peptide YY (PYY) (3-36)-Gly (Human) - Antibody

H-059-08 100 μl
EUR 469.8

Galanin-Like Peptide (GALP) (Human) - Antibody

H-026-51 50 μl
EUR 604.8

[Cys0]-Peptide YY (PYY) (3-19) (Human) - Antibody

H-059-16 100 μl
EUR 469.8

[Cys20]-Peptide YY (PYY) (3-19) (Human) - Antibody

H-059-17 100 μl
EUR 469.8

Peptide-Depleted Plasma (Human)

MB-099-01 2 ml
EUR 119.88

Peptide YY (PYY) (Human) - Purified IgG Antibody

G-059-01 400 μg
EUR 438.48

Peptide YY (PYY) (3-36) (Human)

059-02 200 μg
EUR 102.6

Gastrin Releasing Peptide (GRP) (Human) - Antibody

H-027-07 50 μl
EUR 238.68

RFamide-Related Peptide 1 (RFRP-1) (Human) - Rhodamine Labeled

FR-048-42 1 nmol
EUR 336.96

Stresscopin Related Peptide (SRP) (Human) - Antibody

H-019-27 50 μl
EUR 604.8

C28 optimized peptide 6 (Human)

073-82 100 μg
EUR 235.44

Peptide YY (PYY) (Human) - EIA Kit

EK-059-01 96 wells
EUR 617.76

Peptide YY (PYY) (Human) - RIA Kit

RK-059-01 125 tubes
EUR 814.32

Neuroendocrine Regulatory Peptide 1 (NERP-1) / prepro-VGF (281-306) (Human) - Antibody

H-076-89 100 μl
EUR 336.96

NGR Peptide 1

025-74 200 μg
EUR 184.68

Galanin-Like Peptide (GALP) (Human)

026-51 100 μg
EUR 230.04

PACAP-Related Peptide (PRP) (Human)

052-10 200 μg
EUR 86.4

Bone Forming Peptide 1 (BFP-1) (Human, Rat, Mouse, Bovine, Feline)

080-57 100ug
EUR 196.56

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human)

064-07 200 μg
EUR 114.48

T3 Peptide / Tumstatin (69-88) (Human)

016-50 100 μg
EUR 255.96

T7 Peptide / Tumstatin (74-98) (Human)

016-51 100 μg
EUR 255.96

Galanin-Like Peptide (GALP) (36-60) (Human) - Antibody

H-026-55 50 μl
EUR 604.8

VEGFR-1/FLT-1 antibody

E39-09393 100ug/100ul
EUR 225
Description: Available in various conjugation types.

VEGFR-1/FLT-1 antibody

CAF50629-100ug 100ug
EUR 312

VEGFR-1 / FLT-1 Antibody

abx239393-100ug 100 ug
EUR 577.2

Peptide YY (PYY) (3-36)-Gly (Human)

059-08 100 μg
EUR 282.96

Peptide YY (PYY) (2-36)-Gly (Human)

059-11 100 μg
EUR 267.84

Peptide YY (PYY) (4-36)-Gly (Human)

059-12 100 μg
EUR 267.84

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody

G-064-07 400 μg
EUR 438.48

Gastrin Releasing Peptide (GRP) (Human)

027-07 200 μg
EUR 119.88

Peptide YY (PYY) (3-36) (Human) - Purified IgG Antibody

G-059-02 200 μg
EUR 604.8

Prolactin-Releasing Peptide-31 (PrRP-31) (Human) - Antibody

H-008-50 50 μl
EUR 604.8

[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human) - I-125 Labeled

T-048-43 10 μCi
EUR 1145.88

[Biotinyl-Gln1]-TCAP-1 / Teneurin C-terminal Associated Peptide-1 (Human)

B-020-16 20 μg
EUR 336.96

SHAAG Peptide / Chemokine (46-63) (Human)

072-32 100 μg
EUR 160.92

Stresscopin Related Peptide (SRP) (Human)

019-27 100 μg
EUR 214.92

Human VEGFR1 / FLT1, Fc Tag

E24PHA121 50 μg
EUR 180

Fractalkine Chemokine Domain peptide (41-52) (Human)

026-82 200 μg
EUR 160.92

Fractalkine Chemokine Domain peptide (53-60) (Human)

026-83 200 μg
EUR 135

Fractalkine Chemokine Domain peptide (60-71) (Human)

026-84 200 μg
EUR 160.92

C28 optimized peptide 15 Dimer (Human)

073-86 100 μg
EUR 420.12

Human VEGFR1 / FLT1, His Tag

E24PHA122 50 μg
EUR 225

Neuroendocrine Regulatory Peptide 1 (NERP-1) / prepro-VGF (281-306) (Human)

076-89 100 μg
EUR 214.92

RFamide-Related Peptide 3 (RFRP-3) (Human) - Antibody

H-048-46 100 μl
EUR 604.8

Osteoblast Activating Peptide (OBAP) (Human)

055-52 100 μg
EUR 199.8

Human Proteome Signature Peptide Library

L-010 98 peptides
EUR 7804.08

Peptide YY (PYY) (3-36) (Human) - EIA Kit

EK-059-02 96 wells
EUR 617.76

Peptide YY (PYY) (3-36) (Human) - RIA Kit

RK-059-02 125 tubes
EUR 814.32

Anti-Human VEGFR-3/FLT-4 Antibody

102-PA22 200 µg
EUR 147
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Anti-Human VEGFR-3/FLT-4 Antibody

102-PABi22 50 µg
EUR 157.5
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (FIT1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelia cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Anti-Human VEGFR-3/FLT-4 Antibody

101-M37 100 µg
EUR 199.5
Description: VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.

Anti-Human VEGFR-3/FLT-4 Antibody

101-M38 100 µg
EUR 399
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (Flt1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides which remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

Anti-Human VEGFR-3/FLT-4 Antibody

101-M870 100 µg
EUR 399
Description: Receptor tyrosine Kinase VEGFR-3, also known as FLT4, together with VEGFR1 (Flt1) and VEGFR2 (KDR/Flk-1), are the receptors for vascular endothelial growth factors (VEGF). The VEGFR family belongs to the class II subfamily of receptor tyrosine kinases (RTKs), containing a large extracellular region which is composed of seven Ig-like domains (D1–D7), a single transmembrane (TM) helix and cytoplasmic region with a tyrosine kinase activity. In VEGFR-3, the fifth Ig homology domain is proteolytically cleaved which results in polypeptides which remain linked by two disulfide bonds. VEGFR-3 is widely expressed on all endothelial cells in early embryogenesis, while, in adult tissues, VEGFR-3 expression disappears from the vascular endothelial cells and is observed only on the lymphatic endothelium. VEGF-C and VEGF-D activation of VEGFR-3 plays an important role in the formation of the lymphatic vessel system.

APP 17mer peptide / APP770 (204-220) (Human)

018-74 100 μg
EUR 135

Urotensin II Related Peptide (Human, Rat, Mouse) - Antibody

H-071-17 50 μl
EUR 604.8

C28 optimized peptide 15 Monomer (Human)

073-84 100 μg
EUR 258.12

Recombinant Human FLT-1/VEGFR-1 Protein

RP01137 50μg
EUR 308.75

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit

RK-064-07 125 tubes
EUR 932.04

Peptide YY (PYY) (Human) - I-125 Labeled

T-059-01 10 μCi
EUR 1145.88

Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog)

048-80 500 μg
EUR 177.12

Galanin-Like Peptide (GALP) (Human) - Purified IgG Antibody

G-026-51 200 μg
EUR 604.8

[Tyr0]-Neuroendocrine Regulatory Peptide 1 (NERP-1) (Human) - I-125 Labeled

T-076-93 10 μCi
EUR 1145.88

SHLP2 / Small Humanin-Like Peptide 2 (Human)

018-76 100 μg
EUR 263.52

SHLP3 / Small Humanin-Like Peptide 3 (Human)

018-77 100 μg
EUR 422.28

SHLP4 / Small Humanin-Like Peptide 4 (Human)

018-78 100 μg
EUR 289.44

SHLP5 / Small Humanin-Like Peptide 5 (Human)

018-79 100 μg
EUR 316.44

SHLP6 / Small Humanin-Like Peptide 6 (Human)

018-80 100 μg
EUR 250.56

Galanin-Like Peptide (GALP) (36-60) (Human)

026-55 200 μg
EUR 177.12

FGF23 (188-199 )optimized peptide 10 (Human)

073-88 100 μg
EUR 258.12

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled

FG-064-07A 1 nmol
EUR 336.96

Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401

004-04 100 μg
EUR 140.4

Peptide YY (PYY) (3-36) (Human) - FAM Labeled

FG-059-02A 1 nmol
EUR 336.96

Peptide F 1 (Lobster)

047-62 500 μg
EUR 73.44

Neuroendocrine Regulatory Peptide 1 (NERP-1) / prepro-VGF (281-306) (Human) - Purified IgG Antibody

G-076-89 100 μg
EUR 370.44

Prolactin-Releasing Peptide-31 (PrRP-31) (Human)

008-50 200 μg
EUR 199.8

Prolactin-Releasing Peptide-20 (PrRP-20) (Human)

008-51 200 μg
EUR 199.8

Gastrin Releasing Peptide (GRP) (Human) - Purified IgG Antibody

G-027-07 400 μg
EUR 438.48

Agouti-Related Peptide (AgRP) (83-132) amide (Human) - Antibody

H-003-53 50 μl
EUR 469.8

Gastrin Releasing Peptide (GRP) (18-27) (Human)

027-41 200 μg
EUR 160.92

Agouti-Related Peptide (AgRP) (25-51) (Human)

003-51 200 μg
EUR 129.6

Agouti-Related Peptide (AgRP) (54-82) (Human)

003-52 200 μg
EUR 129.6

Agouti-Related Peptide (AgRP) (25-82) (Human)

003-74 100 μg
EUR 497.88

[Ser3(Des-Octanoyl)]-Ghrelin (1-18) / Motlin-Related Peptide (Human)

031-47 100 μg
EUR 199.8

Seminal Plasma Inhibin-Like Peptide (Human)

034-03 200 μg
EUR 194.4

Galanin-Like Peptide (GALP) (Human) - RIA Kit

RK-026-51 125 tubes
EUR 932.04

Stresscopin Related Peptide (SRP) (Human) - Purified IgG Antibody

G-019-27 200 μg
EUR 604.8

prepro-IGFBP-5 (98-122) peptide 1 (Human, Rat, Mouse, Bovine, Porcine)

033-73 100 μg
EUR 267.84

Peptide YY (PYY) (3-36) (Human) - Biotin Labeled

B-059-02 10 μg
EUR 405

Rabbit Anti-human FLT-1/VEGFR-1 IgG #1, aff pure

FLT11-A 100 ul
EUR 578.4

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled

T-064-07 10 μCi
EUR 1145.88

RFamide-Related Peptide 2 (RFRP-2) (Human)

048-44 500 μg
EUR 177.12

RFamide-Related Peptide 3 (RFRP-3) (Human)

048-46 500 μg
EUR 177.12

Gastrin Releasing Peptide (GRP) (Human) - EIA Kit

EK-027-07 96 wells
EUR 603.72

Gastrin Releasing Peptide (GRP) (Human) - RIA Kit

RK-027-07 125 tubes
EUR 932.04

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC940659-100 100uL
EUR 238.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF594 conjugate, Concentration: 0.1mg/mL

VEGFR1 / Flt-1(FLT1/659) Antibody

BNC940659-500 500uL
EUR 652.8
Description: Primary antibody against VEGFR1 / Flt-1(FLT1/659), CF594 conjugate, Concentration: 0.1mg/mL

Methylation large sets of data provided via out-of-memory representation of the data to provide a responsive loading and analysis capabilities on machines with limited memory.

Results: We developed curatedTCGAData and cBioPortalData R / Bioconductor package to provide an integrated set of data from TCGA multiomic cBioPortal legacy database and web application programming interface using data structures MultiAssayExperiment. This suite of tools provides coordination experimental tests vary with clinicopathological the data with minimal data management burden, as demonstrated through several analysis multiomic pan-cancer and greatly simplified.

Conclusion: This representation allows analysts and developers integrated tools to apply statistical methods and a general plan for comprehensive multiomic data through user-friendly command and documented examples.

Related Posts

Leave a Reply

Your email address will not be published.